Criteria for the initiation of therapy in CLL
| Criteria for the initiation of therapy in CLL (adapted from iwCLL 2018 guidelines) . |
|---|
| Marrow failure: hemoglobin <10 g/dL or platelet count <100 × 109/L |
| Massive, progressive, or symptomatic splenomegaly |
| Massive, progressive, or symptomatic lymphadenopathy |
| Progressive lymphocytosis with ≥50% increase over 2-mo period, or lymphocyte doubling time <6 mo |
| Autoimmune complications poorly responsive to corticosteroids |
| Symptomatic extranodal involvement |
| Disease-related symptoms: weight loss ≥10% over 6 mo, significant fatigue, fevers for 2 or more weeks without infection, night sweats ≥1 mo without infection |
| Criteria for the initiation of therapy in CLL (adapted from iwCLL 2018 guidelines) . |
|---|
| Marrow failure: hemoglobin <10 g/dL or platelet count <100 × 109/L |
| Massive, progressive, or symptomatic splenomegaly |
| Massive, progressive, or symptomatic lymphadenopathy |
| Progressive lymphocytosis with ≥50% increase over 2-mo period, or lymphocyte doubling time <6 mo |
| Autoimmune complications poorly responsive to corticosteroids |
| Symptomatic extranodal involvement |
| Disease-related symptoms: weight loss ≥10% over 6 mo, significant fatigue, fevers for 2 or more weeks without infection, night sweats ≥1 mo without infection |